Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
98.3%
-
Total 13F principal
-
$313,618,710
-
Principal change
-
+$9,128,967
-
Total reported market value
-
$339,699,257
-
Number of holders
-
22
-
Value change
-
+$7,322,635
-
Number of buys
-
11
-
Number of sells
-
12
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q1 2023
As of 31 Mar 2023,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$313,618,710
in principal (par value) of the bond.
The largest 10 bondholders included
D. E. Shaw & Co., Inc., WOLVERINE ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, LAZARD ASSET MANAGEMENT LLC, Linden Advisors LP, BRAIDWELL LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, UBS OCONNOR LLC, AVIVA PLC, and CITIGROUP INC.
This page lists
22
institutional bondholders reporting positions
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.